Pharmaceutical Technology

APRIL 10, 2024

TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.

Clinical Development 147

Clinical Development Antibody Development Drugs 147

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

APRIL 17, 2023

Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.

Antibody 130

Antibody Engineer FDA Approval Development 130

Pharmaceutical Technology

MAY 9, 2023

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130

Drugs Clinical Development Antibody Protein 130

Pharmaceutical Technology

APRIL 13, 2023

Fusion Pharmaceuticals (Fusion) has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107).

Clinical Development 147

Clinical Development Antibody Development Trials 147

Pharmaceutical Technology

MARCH 9, 2023

Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. The clinical development partnership will focus on the development of UCB6114 and UCB4594 investigational antibody candidates.

Antibody 130

Antibody Research Clinical Trials Clinical Trials 130

Pharmaceutical Technology

AUGUST 16, 2022

A first-in-class Trop-2 directed antibody-drug conjugate, Trodelvy is made with a hydrolyzable linker joined to a topoisomerase I inhibitor payload, SN-38. Gilead Sciences Oncology Clinical Research senior vice-president Bill Grossman said: “Trodelvy is approved for second-line metastatic TNBC in over 35 countries.

Medicine 255

Medicine Marketing Development Clinical Development 255

Pharmaceutical Technology

AUGUST 25, 2022

The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5). The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial.

Gene Therapy 264

Gene Therapy Gene Clinical Trials Clinical Trials 264

Pharmaceutical Technology

OCTOBER 25, 2022

Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Astellas will also receive specific rights linked to any possible change of Taysha’s control.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

MAY 25, 2023

Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer.

Antibody 130

Antibody Clinical Trials Clinical Trials Clinical Development 130

Pharmaceutical Technology

SEPTEMBER 30, 2022

Pheon Therapeutics has announced its launch to progress new antibody-drug conjugates (ADCs) for treating solid tumours. The latest financing will aid the company in progressing its lead ADC programme to clinical proof-of-concept (PoC) and validate the new ADC pipeline. .

Antibody 130

Antibody Development Clinical Development Drugs 130

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. billion in milestones – shortly after its own PD-1 drug candidate spartalizumab failed a phase 3 trial in melanoma.

Drugs 98

Drugs Antibody Pharma Companies Development 98

Pharmaceutical Technology

APRIL 4, 2023

Merck has secured approval from the US Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for first-line treatment of some adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC).

Antibody 130

Antibody Containment Clinical Development Trials 130

Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

XTalks

APRIL 15, 2025

Complicated UTIs, on the other hand, occur in individuals with risk factors such as urinary tract abnormalities, catheters, diabetes or drug-resistant bacteria. Wood says AMR is less of a broad concern with Blujepa compared to other drug classes, as its mechanism targeting E. They often require longer or intravenous treatment.

FDA Approval 66

FDA Approval Bacteria DNA Bacterium 66

Pharmaceutical Technology

DECEMBER 7, 2022

The partnership will utilise the Smart Allostery drug discovery platform of HotSpot to develop the first and only small molecule inhibitor of IRF5 for these diseases. HotSpot will also hold a one-time option for sharing international research and development (R&D) expenses in exchange for higher royalties.

Development 147

Development Clinical Development Sales Antibody 147

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. on Tuesday morning, the companys steepest fall in 23 years, according to Bloomberg.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Engineer Development Drugs 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is being developed based on XmAb technology.

Antibody 100

Antibody Engineer Development Drugs 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Antibody 100

Antibody Engineer Development Drugs 100

pharmaphorum

JUNE 28, 2022

billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don’t respond to current immunotherapies. Astellas has agreed a $1.36 The alliance includes an upfront payment of $90 million, backed by $422.5

Antibody 105

Antibody Immune Response Gene Therapy Drugs 105

Pharmaceutical Technology

JANUARY 2, 2023

Lifirafenib maleate is under clinical development by BeiGene and currently in the Phase II in clinical pathway. The drug candidate is administered orally. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. BeiGene overview BeiGene is a biotechnology company.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Amlitelimab is under clinical development by Kymab and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is a humanized monoclonal antibody which acts by targeting OX40L.

Antibody 100

Antibody Clinical Trials Clinical Trials Drugs 100

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. That’s one finding from an early study that tested the injection drug, which mimics the effects of a natural hormone called fibroblast growth factor 21 (FGF21).

Antibody 52

Antibody Drugs Hormones Insulin 52

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

XTalks

JANUARY 6, 2025

Just before the end of 2024, Novo Nordisk nabbed US Food and Drug Administration (FDA) approval for its awaited hemophilia drug Alhemo (concizumab-mtci). However, some patients develop inhibitors antibodies that neutralize the efficacy of replacement therapies. After a five-month suspension, Novo resumed the studies.

FDA Approval 105

FDA Approval Antibody Drugs Clinical Trials 105

Pharmaceutical Technology

FEBRUARY 19, 2023

AT-1412 is under clinical development by Kling Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Clinical Trials Clinical Trials Development 100

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. on Tuesday morning, the company’s steepest fall in 23 years, according to Bloomberg.

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Pharmaceutical Technology

JUNE 5, 2023

Izokibep is under clinical development by Acelyrin and currently in Phase II for Panuveitis. According to GlobalData, Phase II drugs for Panuveitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. It is developed based on affibody technology. Buy the report here.

Antibody 100

Antibody Development Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 19, 2023

Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase I drugs for Kidney Cancer (Renal Cell Cancer) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Clinical Trials Clinical Trials Drugs 100

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

pharmaphorum

SEPTEMBER 26, 2022

The Ministry of Health, Labour and Welfare (MHLW) in Japan has cleared Ezharmia (valemetostat tosylate) based on the results of an open-label phase 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients. Another from Jiangsu Hengrui Medicine (SHR2554) is still in early-stage clinical development.

Drugs 98

Drugs Clinical Trials Clinical Trials Clinical Development 98

Pharmaceutical Technology

FEBRUARY 28, 2023

MCLA-129 is under clinical development by Merus and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. Buy the report here.

Antibody 100

Antibody Development Drugs Clinical Trials 100

pharmaphorum

MAY 20, 2021

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.

Antibody 52

Antibody Development Clinical Development Life Science 52

pharmaphorum

NOVEMBER 16, 2021

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. For now though, any threat from Merck’s drug is speculative.

Trials 98

Trials Drugs Sales Clinical Trials 98